Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied Therapeutics Inc.

0.3326
-0.0004-0.12%
Post-market: 0.33990.0073+2.19%17:21 EDT
Volume:1.87M
Turnover:599.72K
Market Cap:47.09M
PE:-0.44
High:0.3484
Open:0.3450
Low:0.3051
Close:0.3330
Loading ...

William Blair Sticks to Its Hold Rating for Applied Therapeutics (APLT)

TIPRANKS
·
15 Apr

Press Release: Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results

Dow Jones
·
15 Apr

North American Morning Briefing: China Raises Tariffs on U.S. in Latest Salvo

Dow Jones
·
11 Apr

Applied Therapeutics files Form 12b-25 with SEC

TIPRANKS
·
31 Mar

Applied Therapeutics appoints Baumgartner as Chief Regulatory Officer

TIPRANKS
·
19 Mar

Applied Therapeutics Appoints Todd F. Baumgartner, Md, Mph as Chief Regulatory Officer

THOMSON REUTERS
·
19 Mar

Press Release: Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

Dow Jones
·
19 Mar

BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?

Zacks
·
21 Feb

BRIEF-Applied Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance

Reuters
·
11 Feb

Applied Therapeutics Inc - Receives Nasdaq Notice for Minimum Bid Price Non-Compliance

THOMSON REUTERS
·
11 Feb

Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

THOMSON REUTERS
·
21 Jan

Here’s Why Applied Therapeutics, Inc. (NASDAQ:APLT) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Top Calls on Wall Street: Pony AI, Thermo Fisher, Aclaris Therapeutics, and More

The Fly
·
23 Dec 2024

Top Premarket Decliners

MT Newswires Live
·
23 Dec 2024

William Blair Downgrades Applied Therapeutics to Market Perform From Outperform

MT Newswires Live
·
23 Dec 2024

Applied Therapeutics Cut to Market Perform From Outperform by William Blair

Dow Jones
·
23 Dec 2024

William Blair downgrades Applied Therapeutics (APLT) to a Hold

TIPRANKS
·
23 Dec 2024

Penny Stock Applied Therapeutics' FDA Troubles Trigger Investor Lawsuit, Shareholders Claim Deception Over Govorestat Clinical Data

Benzinga
·
21 Dec 2024

Applied Therapeutics Names John Johnson as Executive Chair, Les Funtleyder as Interim CEO

MT Newswires Live
·
20 Dec 2024

RBC Cuts Price Target on Applied Therapeutics to $1.50 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
20 Dec 2024